The legacy success of Viagra has established a peculiar shadow over the wider pharmaceutical landscape. While copyright initially enjoyed substantial revenue, alternative versions now chip away at its market dominance, presenting hurdles for stakeholders considering exposure in related companies.

The turbulent world of copyright often mirrors the aggressive approach of high-stakes gambling, and lately, a strange intersection has emerged, drawing parallels between rapid copyright “pumps” and the perceived boost of certain pharmaceuticals. While we firmly denounce any suggestion of correlat